Sanofi SA
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878
Stocks News & Analysis
stocks
10 best US blue-chip stocks to buy for the long term
personal-finance
Can you achieve global diversification with multinational companies?
stocks
Magnificent Seven vs. the ‘Granolas’: How does Europe’s version stack up?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,631.50 | 42.70 | 0.50% |
CAC 40 | 7,826.79 | 1.34 | -0.02% |
DAX 40 | 24,226.49 | 198.84 | 0.83% |
Dow JONES (US) | 42,343.65 | 740.58 | 1.78% |
FTSE 100 | 8,778.05 | 60.08 | 0.69% |
HKSE | 23,381.99 | 99.66 | 0.43% |
NASDAQ | 19,199.16 | 461.96 | 2.47% |
Nikkei 225 | 37,724.11 | 192.58 | 0.51% |
NZX 50 Index | 12,582.33 | 0.00 | 0.00% |
S&P 500 | 5,921.54 | 118.72 | 2.05% |
S&P/ASX 200 | 8,407.60 | 46.60 | 0.56% |
SSE Composite Index | 3,340.69 | 6.15 | -0.18% |